At groupH, we are constantly learning and challenging ourselves to provide greater insights in our work

Here is a selection of research and publications that give a flavour of topics and events that we found particularly interesting.

All 29 /Autoimmune 0 /Briefing Note 1 /Careers 0 /CNS 0 /Comment 10 /Competitor workshops 0 /Demand assessments 0 /Dermatology 0 /Disease area strategy 0 /Events 0 /Infectious Disesases 0 /Inspiration 1 /Interview 2 /Market landscaping 0 /New Horizons 4 /News 0 /Oncology 0 /Scenario planning workshops 0 /Service Offering 0 /Team 0 /Therapy Area 0 /TPP shaping and validation 0 /Uncategorised 0 /White Papers 11

Forecasting and Data Analytics Presentations – EphMRA 2021

11th June 2021/by groupH

Commercialization Opportunities and Challenges – Gene Therapy

4th June 2021/by groupH

Commercialization Opportunities and Challenges – CAR-Ts

18th May 2021/by groupH

UPDATE: our take on CMS’s latest memo on CAR-T reimbursement

28th August 2019/by groupH

Forecasting and Data Analytics Round Table Discussions – EphMRA 2019

18th July 2019/by groupH

CAR-T Reimbursement in the US – Challenges and an Assessment of Potential Solutions

20th March 2019/by groupH

EU Payer Opinion on Assessing Value in Rare Diseases

3rd December 2018/by groupH

Two countries divided by a common language?

3rd December 2018/by groupH

Forecasting and Data Analytics Round Table Discussion – EphMRA 2018

7th August 2018/by groupH

Approaches to manage ‘affordability’ of high budget impact medicines in key EU countries

2nd August 2018/by groupH

Not if but how – Impressions from Market Access for Cell & Gene Therapies, 18-19th October, London

26th October 2017/by groupH

How accurate are long term sales forecasts?

27th September 2017/by groupH

Does the EU price of Strimvelis create a new ‘glass ceiling’?

1st November 2016/by admin1

Will indication value-based pricing become a reality in Europe?

1st May 2016/by groupH

Enhancing decision makers’ understanding of rare diseases – a case study

1st December 2015/by groupH

Real World Pharma – Affordability vs. Cost Effectiveness. Impressions from 18th ISPOR in Milan

1st November 2015/by admin1

The payers’ perspective on gene therapies: groupH details its study in Nature Biotechnology

10th September 2015/by groupH

groupH’s strategic Market Access practice reports favourable payer views on novel long-acting injectables

1st March 2015/by groupH

How groupH can assist in developing Market Access strategies

1st September 2014/by groupH

Pharmaceutical forecasting: throwing darts or adding value?

1st November 2013/by groupH

Maximizing the Value of Early Engagement Between Manufacturers, Payers and Regulators in Europe

1st November 2013/by groupH

Manage your energy, not your time

1st July 2013/by groupH

Keeping abreast of changing dynamics in the Japanese Pharma market

1st June 2013/by groupH

Will new developments change the treatment paradigm in RA?

1st April 2013/by groupH

Fresh approaches to visualising information

1st March 2013/by groupH

Newcomers entering the anti-obesity market bring optimism, but face tough challenges

1st February 2013/by groupH

One way we are aiming to create shared value

1st November 2012/by groupH

Eugene Tierney, former Head of Central Nervous System at Roche

1st September 2012/by groupH

The New Role of Payer Advisory Boards in Shaping Clinical Development Preparation, Structure, Outcomes and Key Success Factors

1st February 2012/by groupH